Pfizer planning to merge off-patent drug business with Mylan

30 Jul 2019 Evaluate

Pfizer is planning to merger its off-patent drug business with generic drugmaker Mylan to create a global leader in low-cost treatment. The new entity, which will be renamed upon the deal's closure, will have a portfolio that includes impotence drug Viagra, cholesterol pills Lipitor, painkiller Lyrica, and the life-saving EpiPen allergy treatment.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.

Pfizer Share Price

4595.60 -127.70 (-2.70%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×